Butyrylcholinesterase genotype and enzyme activity in relation to Gulf War illness: Preliminary evidence of gene-exposure interaction from a case-control study of 1991 Gulf War veterans

Environmental Health: A Global Access Science Source

Volumn 14, Issue 1, 2015, Pages

  Steele, Lea ^a   Lockridge, Oksana ^b   Gerkovich, Mary M ^c   Cook, Mary R ^d   Sastre, Antonio ^e  

^a BAYLOR UNIVERSITY   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^d MRIGlobal   (United States)

^e NONE   (United States)

Author keywords

Butyrylcholinesterase; Gene environment interaction; Gulf War illness; Gulf War veterans; Pyridostigmine bromide

Indexed keywords

CHOLINESTERASE; PYRIDOSTIGMINE;

ABNORMALITY; BROMINE COMPOUND; ENZYME ACTIVITY; ETIOLOGY; GENETIC VARIATION; GENOTYPE-ENVIRONMENT INTERACTION; HEALTH RISK; POST-WAR; SPATIOTEMPORAL ANALYSIS;

ADULT; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; ENZYME ACTIVITY; EXPERIENCE; FEMALE; GENETIC DIFFERENCE; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERSIAN GULF SYNDROME; PRIORITY JOURNAL; RISK ASSESSMENT; VETERAN; CASE CONTROL STUDY; CHEMICALLY INDUCED; ENVIRONMENTAL EXPOSURE; GENETICS; GENOTYPE; METABOLISM; SOLDIER; WAR;

ADULT; BUTYRYLCHOLINESTERASE; CASE-CONTROL STUDIES; ENVIRONMENTAL EXPOSURE; FEMALE; GENOTYPE; GULF WAR; HUMANS; MALE; MIDDLE AGED; MILITARY PERSONNEL; PERSIAN GULF SYNDROME; PYRIDOSTIGMINE BROMIDE; VETERANS;

EID: 84988923255     PISSN: None     EISSN: 1476069X     Source Type: Journal    
DOI: 10.1186/1476-069X-14-4     Document Type: Article

References (60)

1. Steele L. Prevalence and patterns of Gulf War illness in Kansas veterans: association of symptoms with characteristics of person, place, and time of military service. Am J Epidemiol. 2000;152:992-1002.
2. Research Advisory Committee on Gulf War Veterans' Illnesses. Gulf War Illness and the Health of Gulf War Veterans. Washington, DC: U.S. Government Printing Office; 2008.
3. Kang HK, Li B, Mahan CM, Eisen SA, Engel CC. Health of US veterans of 1991Gulf War: a follow-up survey in 10 years. J Occup Environ Med. 2009;51:401-10.
4. Institute of Medicine (IOM). Gulf War and Health: Volume 8 - Health Effects of Serving in the Gulf War. Washington, DC: National Academy Press; 2010.
5. Ozakinci G, Hallman WK, Kipen HM. Persistence of symptoms in veterans of the First Gulf War: 5-year follow-up. Environ Health Perspect. 2006;114:1553-7.
6. Kang HK. Reported unexplained multisymptom illness among veterans who participated in the VA longitudinal health study of Gulf War era veterans. Presented at: Meeting of the Research Advisory Committee on Gulf War Veterans' Illnesses. Washington, D.C:; 2005. [http://www.va.gov/RAC-GWVI/docs/ Minutes-and-Agendas/Minutes-Sep2005-AppendixA-Presentation19.pdf]
7. Chao LL, Abadjian L, Hlavin J, Meyerhoff DJ, Weiner MW. Effects of low-level sarin and cyclosarin exposure and Gulf War Illness on brain structure andfunction: a study at 4 T. Neurotoxicology. 2011;32:814-22.
8. Rayhan RU, Stevens BW, Timbol CR, Adewuyi O, Walitt B, VanMeter JW, et al. Increased brain white matter axial diffusivity associated with fatigue, pain and hyperalgesia in Gulf War illness. PLoS One. 2013;8:e58493.
9. Sullivan K, Krengel M, Proctor SP, Devine S, Heeren T, White RF. Cognitive functioning in treatment-seeking Gulf War veterans: pyridostigmine bromide use and PTSD. J Psychopathol Behav Assess. 2003;25:95-103.
10. Toomey R, Alpern R, Vasterling JJ, Baker DG, Reda DJ, Lyons MJ, et al. Neuropsychological functioning of U.S. Gulf War veterans 10 years after the war. J Int Neuropsychol Soc. 2009;15:717-29.
11. Haley RW, Vongpatanasin W, Wolfe GI, Bryan WW, Armitage R, Hoffman RF, et al. Blunted circadian variation in autonomic regulation of sinus node function in veterans with Gulf War syndrome. Am J Med. 2004;117:469-78.
12. Stein PK, Domitrovich PP, Ambrose K, Lyden A, Fine M, Gracely RH, et al. Sex effects on heart rate variability in fibromyalgia and Gulf War illness. Arthritis Rheum. 2004;51:700-8.
13. Haley RW, Charuvastra E, Shell WE, Buhner DM, Marshall WW, Biggs MM, et al. Cholinergic autonomic dysfunction in veterans with Gulf War illness: confirmation in a population-based sample. JAMA Neurol. 2013;70:191-200.
14. Zhang Q, Zhou XD, Denny T, Ottenweller JE, Lange G, LaManca JJ, et al. Changes in immune parameters seen in Gulf War veterans but not in civilians with chronic fatigue syndrome. Clin Diagn Lab Immunol. 1999;6:6-13.
15. Vojdani A, Thrasher JD. Cellular and humoral immune abnormalities in Gulf War veterans. Environ Health Perspect. 2004;112:840-6.
16. Whistler T, Fletcher MA, Lonergan W, Zeng XR, Lin JM, Lapierriere A, et al. Impaired immune function in Gulf War Illness. BMC Med Genomics. 2009;2:12.
17. Broderick G, Ben-Hamo R, Vashishtha S, Efroni S, Nathanson L, Barnes Z, et al. Altered immune pathway activity under exercise challenge in Gulf War Illness: an exploratory analysis. Brain Behav Immun. 2013;28:159-69.
18. Golier JA, Schmeidler J, Legge J, Yehuda R. Enhanced cortisol suppression to dexamethasone associated with Gulf War deployment. Psychoneuroendocrinology. 2006;31:1181-9.
19. Golier JA, Schmeidler J, Legge J, Yehuda R. Twenty-four hour plasma cortisol and adrenocorticotropic hormone in Gulf War veterans: relationships to posttraumatic stress disorder and health symptoms. Biol Psychiatry. 2007;62:1175-8.
20. Research Advisory Committee on Gulf War Veterans' Illnesses. Gulf War Illness and the Health of Gulf War Veterans: Research Update and Recommendations, 2009-2013. Washington, DC: U.S. Government Printing Office; 2014.
21. Steele L, Sastre A, Gerkovich MM, Cook MR. Complex factors in the etiology of Gulf War illness: wartime exposures and risk factors differ in veteran subgroups. Environ Health Perspect. 2012;120:112-8.
22. Fricker Jr RD, Reardon E, Spektor DM, Cotton SK, Hawes-Dawson J, Pace JE, et al. Pesticide Use During the Gulf War: A Survey of Gulf War Veterans. Arlington, VA: National Defense Research Institute (RAND); 2000.
23. U.S. Department of Defense. Environmental Exposure Report: Pesticides Final Repor. Washington, DC: Office of the Special Assistant to the Undersecretary of Defense for Gulf War Illnesses Medical Readiness and Military Deployments; 2003.
24. U.S. Department of Defense. Case Narrative: U.S. Demolition Operations at Khamasiyah, Final Report. Washington, DC: Office of the Special Assistant to the Undersecretary of Defense for Gulf War Illnesses Medical Readiness and Military Deployments; 2002.
25. Cherry N, Creed F, Silman A, Dunn G, Baxter D, Smedley J, et al. Health and exposures of United Kingdom Gulf war veterans. Part II: the relation of health to exposure. Occup Environ Med. 2001;58:299-306.
26. Wolfe J, Proctor SP, Erickson DJ, Hu H. Risk factors for multisymptom illness in US Army veterans of the Gulf War. J Occup Environ Med. 2002;44:271-81.
27. Nisenbaum R, Barrett DH, Reyes M, Reeves WC. Deployment stressors and a chronic multisymptom illness among Gulf War veterans. J Nerv Ment Dis. 2000;188:259-66.
28. Lockridge O, Masson P. Pesticides and susceptible populations: people with butyrylcholinesterase genetic variants may be at risk. Neurotoxicology. 2000;21:113-26.
29. Gatke MR, Viby-Mogensen J, Ostergaard D, Bundgaard JR. Response to mivacurium in patients carrying the k variant in the butyrylcholinesterase gene. Anesthesiology. 2005;102:503-8.
30. Lockridge O. Genetic variants of human serum cholinesterase influence metabolism of the muscle relaxant succinylcholine. Pharmacol Ther. 1990;47:35-60.
31. Loewenstein-Lichtenstein Y, Schwarz M, Glick D, Norgaard-Pedersen B, Zakut H, Soreq H. Genetic predisposition to adverse consequences of anticholinesterases in "atypical" BCHE carriers. Nat Med. 1995;1:1082-5.
32. Fukuda K, Nisenbaum R, Stewart G, Thompson WW, Robin L, Washko RM, et al. Chronic multisymptom illness affecting Air Force veterans of the Gulf War. JAMA. 1998;280:981-8.
33. Bartels CF, Jensen FS, Lockridge O, van der Spek AF, Rubinstein HM, Lubrano T, et al. DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. Am J Hum Genet. 1992;50:1086-103.
34. Bartels CF, James K, La Du BN. DNA mutations associated with the human butyrylcholinesterase J-variant. Am J Hum Genet. 1992;50:1104-14.
35. Jensen FS, Nielsen LR, Schwartz M. Detection of the plasma cholinesterase K variant by PCR using an amplification-created restriction site. Hum Hered. 1996;46:26-31.
36. Nogueira CP, Bartels CF, McGuire MC, Adkins S, Lubrano T, Rubinstein HM, et al. Identification of two different point mutations associated with the fluoride-resistant phenotype for human butyrylcholinesterase. Am J Hum Genet. 1992;51:821-8.
37. Sudo K, Maekawa M, Akizuki S, Magara T, Ogasawara H, Tanaka T. Human butyrylcholinesterase L330I mutation belongs to a fluoride-resistant gene, by expression in human fetal kidney cells. Biochem Biophys Res Commun. 1997;240:372-5.
38. McGuire MC, Nogueira CP, Bartels CF, Lightstone H, Hajra A, Van der Spek AF, et al. Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase. Proc Natl Acad Sci U S A. 1989;86:953-7.
39. SAS Institute Inc. SAS Statistical Software, Version 9.2. Cary, NC: SAS Institute; 2009.
40. Lepage L, Schiele F, Gueguen R, Siest G. Total cholinesterase in plasma: biological variations and reference limits. Clin Chem. 1985;31:546-50.
41. Furlong CE, Li WF, Richter RJ, Shih DM, Lusis AJ, Alleva E, et al. Genetic and temporal determinants of pesticide sensitivity: role of paraoxonase (PON1). Neurotoxicology. 2000;21:91-100.
42. Li B, Sedlacek M, Manoharan I, Boopathy R, Duysen EG, Masson P, et al. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol. 2005;70:1673-84.
43. Furlong CE. PON1 status and neurologic symptom complexes in Gulf War veterans. Genome Res. 2000;10:153-5.
44. Kamel F, Hoppin JA. Association of pesticide exposure with neurologic dysfunction and disease. Environ Health Perspect. 2004;112:950-8.
45. Lockridge O. Butyrylcholinesterase Genetic Variants in Persons with Gulf War Illness. Fort Detrick, MD: U.S. Army Medical Research and Materiel Command; 1999 [http://www.gulflink.osd.mil/medsearch/GeneticStudies/ DoD60.shtml]
46. Haley RW, Billecke S, La Du BN. Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans. Toxicol Appl Pharmacol. 1999;157:227-33.
47. Concato J, Aslan M, Palmisano MM, Doebbeling CC, Peduzzi P, Ofek K, et al. Acetylcholinesterase activity in veterans of the first Gulf War. J Investig Med. 2007;55:360-7.
48. Mackness B, Durrington PN, Mackness MI. Low paraoxonase in Persian Gulf War Veterans self-reporting Gulf War Syndrome. Biochem Biophys Res Commun. 2000;276:729-33.
49. Hotopf M, Mackness MI, Nikolaou V, Collier DA, Curtis C, David A, et al. Paraoxonase in Persian Gulf War veterans. J Occup Environ Med. 2003;45:668-75.
50. Fontoura-da-Silva SE, Chautard-Freire-Maia EA. Butyrylcholinesterase variants (BCHE and CHE2 Loci) associated with erythrocyte acetylcholinesterase inhibition in farmers exposed to pesticides. Hum Hered. 1996;46:142-7.
51. Howard TD, Hsu FC, Grzywacz JG, Chen H, Quandt SA, Vallejos QM, et al. Evaluation of candidate genes for cholinesterase activity in farmworkers exposed to organophosphorus pesticides: association of single nucleotide polymorphisms in BCHE. Environ Health Perspect. 2010;118:1395-9.
52. Abou-Donia MB, Dechkovskaia AM, Goldstein LB, Abdel-Rahman A, Bullman SL, Khan WA. Co-exposure to pyridostigmine bromide, DEET, and/or permethrin causes sensorimotor deficit and alterations in brain acetylcholinesterase activity. Pharmacol Biochem Behav. 2004;77:753-62.
53. Somani SM, Husain K, Asha T, Helfert R. Interactive and delayed effects of pyridostigmine and physical stress on biochemical and histological changes in peripheral tissues of mice. J Appl Toxicol. 2000;20:327-34.
54. Beck KD, Zhu G, Beldowicz D, Brennan FX, Ottenweller JE, Moldow RL, et al. Central nervous system effects from a peripherally acting cholinesterase inhibiting agent: interaction with stress or genetics. Ann N Y Acad Sci. 2001;933:310-4.
55. Servatius RJ, Ottenweller JE, Beldowicz D, Guo W, Zhu G, Natelson BH. Persistently exaggerated startle responses in rats treated with pyridostigmine bromide. J Pharmacol Exp Ther. 1998;287:1020-8.
56. Giacobini E. Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol Res. 2004;50:433-40.
57. Hartmann J, Kiewert C, Duysen EG, Lockridge O, Greig NH, Klein J. Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity. J Neurochem. 2007;100:1421-9.
58. Mesulam MM, Guillozet A, Shaw P, Levey A, Duysen EG, Lockridge O. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience. 2002;110:627-39.
59. Spencer PS, McCauley LA, Lapidus JA, Lasarev M, Joos SK, Storzbach D. Self-reported exposures and their association with unexplained illness in a population-based case-control study of Gulf War veterans. J Occup Environ Med. 2001;43:1041-56.
60. U.S. Food and Drug Administration. Pyridostigmine Bromide Information Page. [http://www.fda.gov/Drugs/EmergencyPreparedness/Bioterrorismand DrugPreparedness/ucm130341.htm]